Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients

Khansa Ahsan, Munir Ahmad Anwar, Nayla Munawar

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Coronavirus disease 2019 (COVID-19) infection caused by the severe acute respiratory syndrome coronavirus 2 virus, its symptoms, treatment, and post-COVID-19 effects have been a major focus of research since 2020. In addition to respiratory symptoms, different clinical variants of the virus have been associated with dynamic symptoms and multiorgan diseases, including liver abnormalities. The release of cytokines by the activation of innate immune cells during viral infection and the high doses of drugs used for COVID-19 treatment are considered major drivers of liver injury in COVID-19 patients. The degree of hepatic inflammation in patients suffering from chronic liver disease and having COVID-19 could be severe and can be estimated through different liver chemistry abnormality markers. Gut microbiota influences liver chemistry through its metabolites. Gut dysbiosis during COVID-19 treatment can promote liver inflammation. Here, we highlighted the bidirectional association of liver physiology and gut microbiota (gut-liver axis) and its potential to manipulate drug-induced chemical abnormalities in the livers of COVID-19 patients.

Original languageEnglish
Pages (from-to)1708-1720
Number of pages13
JournalWorld Journal of Gastroenterology
Issue number11
Publication statusPublished - Mar 21 2023


  • COVID-19
  • Cytokines
  • Gut microbiome
  • Gut-liver axis
  • Prebiotics
  • Probiotics

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients'. Together they form a unique fingerprint.

Cite this